DWC20155

DWC20155 is an investigational small molecule drug developed by Daewoong Pharmaceutical. It has been studied primarily in combination with DWC20156, with clinical trials focusing on its safety, pharmacokinetics, and potential efficacy for gastrointestinal conditions such as gastritis and ulcers. The mechanism of action for DWC20155 has not been publicly defined or disclosed in available sources. Clinical studies have included healthy volunteers to assess drug-drug interactions and pharmacokinetic profiles when co-administered with other agents[1][2][3][4][5][6]. There is no evidence that it has reached approval or late-stage development for any indication.